1. HLA Does Not Impact on Short-Medium-Term Antibody Response to Preventive Anti-SARS-Cov-2 Vaccine
- Author
-
Maria Lina Tornesello, Luigi Buonaguro, Roberta Penta, Gerardo Botti, Ernesta Cavalcanti, Maria Tagliamonte, Concetta Ragone, Pasqualina C. Fiorillo, Attilio Antonio Montano Bianchi, Leonardo Miscio, Serena Meola, Laura Auriemma, and Franco M. Buonaguro
- Subjects
0301 basic medicine ,COVID-19 Vaccines ,Immunology ,Antibody Affinity ,Human leukocyte antigen ,Antibodies, Viral ,HLA-DQ antigens ,03 medical and health sciences ,0302 clinical medicine ,Antigen ,medicine ,Immunology and Allergy ,Humans ,Allele ,antibody titer level ,Antigens, Viral ,B cell ,HLA-DR Antigen ,BNT162 Vaccine ,Original Research ,chemistry.chemical_classification ,HLA-D Antigens ,HLA-DQ Antigen ,business.industry ,SARS-CoV-2 ,HLA-DR antigens ,COVID-19 ,BNT162b2 mRNA COVID-19 vaccine ,RC581-607 ,Titer ,030104 developmental biology ,medicine.anatomical_structure ,chemistry ,030220 oncology & carcinogenesis ,Spike Glycoprotein, Coronavirus ,Immunologic diseases. Allergy ,Glycoprotein ,business - Abstract
The response to anti-SARS-Cov-2 preventive vaccine shows high interpersonal variabilityat short and medium term. One of the explanations might be the individual HLA allelicvariants. Indeed, B cell response is stimulated and sustained by CD4+ T helper cells activated by antigens presented by HLA-class II alleles on antigen-presenting cells (APCs). The impact of the number of antigens binding to HLA class-II alleles on the antibodyresponse to the COVID vaccine has been assessed in a cohort of 56 healthcare workerswho received the full schedule of the Pfizer-BioNTech BNT162b2 vaccine. Such vaccine isbased on the entire spike protein of the SARS-CoV-2. Ab titers have been evaluated 2weeks after the first dose as well as 2 weeks and 4 months after the boosting dose. HLADRB1and DBQ1 for each of the vaccinees have been assessed, and strong binders havebeen predicted. The analysis showed no significant correlation between the shortmedium-term Ab titers and the number of strong binders (SB) for each individual. These results indicate that levels of Ab response to the spike glycoprotein is not dependent on HLA class II allele, suggesting an equivalent efficacy at global level of thecurrently used vaccines. Furthermore, the pattern of persistence in Ab titer does notcorrelate with specific alleles or with the number of SBs.
- Published
- 2021
- Full Text
- View/download PDF